Loading patent…
AssigneesSynerGene Therapeutics, Inc., Georgetown University
InventorsEsther H. Chang, Joe B. Harford, Sang Soo Kim
Estimating the term…
This invention provides methods to overcome the current limitations of immune checkpoint immunotherapy to provide more effective methods of treating cancer. In embodiments this invention provides a means of using of p53 gene therapy to augment immune checkpoint inhibition by combining antibodies targeting immune checkpoint molecules with SGT-53, a nanomedicine carrying a plasmid encoding human wild-type p53. This invention provides means of increasing tumor immunogenicity, enhancing both innate and adaptive immune responses, and reducing tumor-induced immunosuppression, sensitizing otherwise refractory tumors to anti-immune checkpoint antibodies. In other embodiments this invention also unexpectedly reduces immune-related toxicities that are seen with immunotherapies.
A method of treating a cancer in a patient, consisting of:
Dependencies are inferred from the claim text.